Despite the safety and efficacy of biosimilars — and the potential cost savings they offer — uptake among private payers has been low historically and is only starting to gain steam, said Neda Nasseri, pharmacist and private payer product director at Desjardins Insurance, during Benefits Canada’s 2023 Face to Face Drug Plan Management Forum in December. The insurer first developed […]
It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans, said John Adams, chair of the board of directors for patient advocacy group Best Medicines Coalition, during a session at Benefits Canada’s 2023 Face […]
The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]
A story on how plan sponsors and insurers are considering covering weight-loss drugs as part of a broader push towards more inclusive benefits was the most-read benefits story on BenefitsCanada.com this year. Here are the 10 most popular benefits news stories of the year: 1. How plan sponsors, insurers are considering coverage of weight-loss drugs amid rising […]
TD Synnex Canada is modernizing its employee benefits plan by getting the best value for money while still protecting employees from a mental-health and well-being perspective, according to Shana Kapustin, the global information technology company’s senior director of human resources, speaking during an event hosted last week by the Group Insurance and Pharmaceutical Committee. “We’ve gone […]
An article on how global pension funds compare in terms of transparency was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Five Canadian pension funds receive top scores for transparency: benchmark 2. How plan sponsors, insurers are considering coverage of weight-loss drugs amid rising use […]
The annual Benefits & Pension Summit, which was hosted virtually on June 1, is the only Benefits Canada event that brings together health benefits and capital accumulation plans in one event. This year, delegates heard the results of Benefits Canada‘s exclusive CAP Member Survey with a panel of experts discussing the findings, case studies from two leading […]
Three main drug categories — diabetes, asthma and stimulants for attention deficit hyperactivity disorder — accounted for rising drug claims in 2022, according to Lavina Viegas, Telus Health’s director of client account management, speaking during Benefits Canada‘s 2023 Benefits & Pension Summit in June. Referring to Telus Health’s 2023 drug plan trends report, she said […]
With Yukon implementing a transitioning policy on April 3 to expand the use of biosimilar medicines in its public drug plan, it’s important for benefits plan sponsors that create a similar policy for their workplace plans to be clear in their communication and education with employees. “It’s never easy to switch a medication, especially when […]
Three years ago this month, the world was grappling with the early days of the coronavirus pandemic. Even then, with very little information available, people were beginning to turn their attention to the anticipated long-term ramifications of the public health crisis. With everyone experiencing this once-in-a-century moment simultaneously, no one had a response for how […]